Celldex Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2011 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Celldex Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2011 to Q4 2023.
  • Celldex Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $347M, a 11.1% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $347M +$34.6M +11.1% Dec 31, 2023 10-K 2024-02-26
Q4 2022 $313M +$10.2M +3.38% Dec 31, 2022 10-K 2024-02-26
Q4 2021 $303M +$11.2M +3.83% Dec 31, 2021 10-K 2023-02-28
Q4 2020 $291M +$956K +0.33% Dec 31, 2020 10-K 2022-02-28
Q4 2019 $290M -$2.93M -1% Dec 31, 2019 10-K 2021-03-29
Q4 2018 $293M +$28.8M +10.9% Dec 31, 2018 10-K 2020-03-26
Q4 2017 $265M -$66.3M -20% Dec 31, 2017 10-K 2019-03-07
Q4 2016 $331M +$56.6M +20.6% Dec 31, 2016 10-K 2018-03-07
Q4 2015 $274M +$57.1M +26.3% Dec 31, 2015 10-K 2017-03-14
Q4 2014 $217M +$48.6M +28.8% Dec 31, 2014 10-K/A 2016-02-25
Q4 2013 $169M +$35.8M +26.9% Dec 31, 2013 10-K 2015-02-24
Q4 2012 $133M +$22.2M +20.1% Dec 31, 2012 10-K 2014-03-03
Q4 2011 $111M Dec 31, 2011 10-K 2013-03-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.